Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > No one can predict when or if approvals will happen.

<< Previous

Bullboard Posts

Next >>

Comment by SamV21on Sep 20, 2021 1:05pm

98 Views

Post# 33886983

RE:RE:RE:No one can predict when or if approvals will happen.

No one can predict if approvals will ever happen, Teva and Tilray didn't want to waste money on it as the medical community will not replace one addictive med .with another, where you need so much THC it makes patients unable to function.Even if it is approved they will never replace opioids , wishful thinking on Tetras part , need to be realistic here.Dead end road here, paid job for Guy research thats all this will ever be.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario